Modulation of estrogenic action in clear cell carcinoma of the ovary (Review)

被引:27
作者
Tanase, Yasuhito [1 ]
Yamada, Yoshihiko [1 ]
Shigetomi, Hiroshi [1 ]
Kajihara, Hirotaka [1 ]
Oonogi, Akira [1 ]
Yoshizawa, Yoriko [1 ]
Furukawa, Naoto [1 ]
Haruta, Shoji [1 ]
Yoshida, Shozo [1 ]
Sado, Toshiyuki [1 ]
Oi, Hidekazu [1 ]
Kobayashi, Hiroshi [1 ]
机构
[1] Nara Med Univ, Dept Obstet & Gynecol, Kashihara, Nara 6348522, Japan
基金
日本学术振兴会;
关键词
clear cell carcinoma of the ovary; oxidative stress; estrogen receptor; chromatin remodeling; HEPATOCYTE NUCLEAR FACTOR-1-BETA; CPG ISLAND; CANCER; ENDOMETRIOSIS; EXPRESSION; IDENTIFICATION; MUTATIONS; CHEMOTHERAPY; PATHOGENESIS; METHYLATION;
D O I
10.3892/etm.2011.376
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Two histologic types, clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC), are the common histology in ovarian cancer patients who have associated endometriosis. However, both tumor types have distinct clinicopathological characteristics and molecular phenotypes. EAC is predominantly positive for estrogen receptor (ER), but CCC specifically exhibits lower ER expression. This study reviews the current understanding of the role of the ER information in the pathogenesis of CCC, as well as the English language literature for biochemical studies on ER expression and estrogenic action in CCC. The iron-mediated oxidative stress occurs due to repeated hemorrhage in endometriosis, then this compound oxidatively modifies genomic DNA and, subsequently, ER depletion may be observed. There are a number of factors that interfere with ER expression and estrogen activity, which include DNA methylation of the promoter region, histone deacetylation, heme and iron binding, chromatin remodeling and ubiquitin ligase activity. Loss of estrogen function may be a turning point in CCC progression and aggressiveness.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 39 条
[1]   Origins and molecular pathology of ovarian cancer [J].
Bell, DA .
MODERN PATHOLOGY, 2005, 18 :S19-S32
[2]   The Origin of Ovarian Cancer - Is It Getting Clearer? [J].
Birrer, Michael J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (16) :1574-1575
[3]   Estrogen receptor subtypes in ovarian cancer - A clinical correlation [J].
Chan, Karen K. L. ;
Wei, Na ;
Liu, Stephanie S. ;
Xiao-Yun, Liao ;
Cheung, Annie N. ;
Ngan, Hextan Y. S. .
OBSTETRICS AND GYNECOLOGY, 2008, 111 (01) :144-151
[4]  
Conte D, 1996, J BIOL CHEM, V271, P5125
[5]  
Dannenmann C, 2008, CANCER BIOL THER, V7, P1460
[6]   Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer [J].
Dinulescu D.M. ;
Ince T.A. ;
Quade B.J. ;
Shafer S.A. ;
Crowley D. ;
Jacks T. .
Nature Medicine, 2005, 11 (1) :63-70
[7]   Oxidative Stress and DNA Methylation in Prostate Cancer [J].
Donkena, Krishna Vanaja ;
Young, Charles Y. F. ;
Tindall, Donald J. .
OBSTETRICS AND GYNECOLOGY INTERNATIONAL, 2010, 2010
[8]   Epigenetic information and estrogen receptor alpha expression in breast cancer [J].
Giacinti, Laura ;
Claudio, Pier Paolo ;
Lopez, Massimo ;
Giordano, Antonio .
ONCOLOGIST, 2006, 11 (01) :1-8
[9]   Activation of ATP-binding cassette transporter A1 transcription by chromatin remodeling complex [J].
Huuskonen, J ;
Vishnu, M ;
Fielding, PE ;
Fielding, CJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (06) :1180-1185
[10]   Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma [J].
Itamochi, Hiroaki ;
Kigawa, Junzo ;
Terakawa, Naoki .
CANCER SCIENCE, 2008, 99 (04) :653-658